AZ’s drug reduces risk of symptomatic COVID by 77%

AstraZeneca said on Friday its monoclonal antibody drug AZD7442 reduces the risk of developing symptomatic case of COVID-19 by 77%.

A pre-exposure prophylaxis trial that included 5,197 participants s…